Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma.

Thyroid : official journal of the American Thyroid Association - 1 Nov 2013

Kim Min-Hee, Ko Sun Hee, Bae Ja-Seong, Lee Sung-Hak, Jung Chan-Kwon, Lim Dong-Jun, Baek Ki-Hyun, Kim Sung-Hoon, Lee Jong-Min, Kang Moo-Il, Cha Bong-Yun

Abstract excerpt

BACKGROUND: FDG (2-[(18)F]Fluoro-2-D-deoxyglucose-positron emission tomography (PET)/computed tomography (CT), which can detect a change in glucose metabolism in cancer cells, has been introduced as a diagnostic and prognostic tool in papillary thyroid carcinoma (PTC). However, differences in the clinicopathological and biological characteristics between primary PTCs with FDG uptake and those without FDG uptake...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Papillary
Share to Fluorodeoxyglucose F18

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucose Transporter Type 1

Share to Hypoxia-Inducible Factor 1, alpha Subunit

Share to Multimodal Imaging

Share to Positron-Emission Tomography

Share to Radiopharmaceuticals

Share to Thyroid Cancer, Papillary

Source

Identifiers

PMID: 23688271
DOI: 10.1089/thy.2013.0051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma.PMID 23688271Read ↗

Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.Semantic proximity Read ↗

Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer.Semantic proximity Read ↗

THE RELATIONSHIP OF BRAFV600E MUTATION STATUS TO FDG PET/CT AVIDITY IN THYROID CANCER: A REVIEW AND META-ANALYSIS.Semantic proximity Read ↗

Correlation of BRAF mutation and SUVmax levels in thyroid cancer patients incidentally detected in 18F-fluorodeoxyglucose positron emission tomography.Semantic proximity Read ↗

Relationship Between 18F-fluorodeoxyglucose Accumulation and the BRAF V600E Mutation in Papillary Thyroid Cancer.Semantic proximity Read ↗

Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.Semantic proximity Read ↗

mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas.Semantic proximity Read ↗

Association between macrocalcification and papillary thyroid carcinoma and corresponding valuable diagnostic tool: retrospective study.Semantic proximity Read ↗

Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.Semantic proximity Read ↗

PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma.Semantic proximity Read ↗

Clinico-pathological factors and 18 F-FDG PET/CT metabolic parameters for prediction of progression-free survival in Radioiodine Refractory Differentiated Thyroid CarcinomaSemantic proximity Read ↗

BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.